Pacira | PCRX - Cost Of Sales


Pacira reported $58.49M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Astellas Pharma JPY 158.38B 28.94B Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8B 67M Jun/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novo Nordisk DKK 17.1B 3.5B Jun/2026
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 58.49M 7.75M Jun/2026
Perrigo USD 708.9M 65.2M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026
Teva Pharmaceutical Industries USD 1.98B 30M Jun/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026
Zoetis USD 704M 32M Jun/2026